title: Gastroenteropancreatic neuroendocrine tumours: an overview.
abstract: Gastroenteropancreatic neuroendocrine tumours (GEP-NET) represent a heterogeneous family of diseases of often challenging clinical management. Although many GEP-NET are slow progressing and frequently less aggressive than neoplasms of other origin, they can metastasise and reduce the life span of the patient. GEP-NET can be functioning (secreting hormones that may cause symptoms and organ damage), but some 60% are non-functioning. Thorough clinical assessment including family history, biochemical tests, radiology and nuclear medicine scans, and histological confirmation are important to tailor the optimal treatment of GEP-NET, which should be managed with a multidisciplinary approach and mainly guided by tumour grading and staging, functioning status, and location of the primary lesion.
authors.affiliation: Neuroendocrine Specialist Nurse, ARDEN NET Centre, European Neuroendocrine Tumour Society Centre of Excellence, University Hospitals Coventry and Warwickshire NHS Trust.
authors.forename: Louise
authors.initials: L
authors.lastname: Davies
authors.affiliation: Lead The ARDEN NET Centre, European Neuroendocrine Tumour Society (ENETS) Centre of Excellence, University Hospitals Coventry & Warwickshire NHS Trust (UHCW); and Centre for Applied Biological and Exercise Sciences, Coventry University.
authors.forename: Martin O
authors.initials: MO
authors.lastname: Weickert
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood / Q000652:urine; D015331:Cohort Studies; D005060:Europe / Q000453:epidemiology; D006801:Humans; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D018358:Neuroendocrine Tumors / Q000175:diagnosis* / Q000188:drug therapy* / Q000451:nursing; D010190:Pancreatic Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000451:nursing; D013004:Somatostatin / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D013004:Somatostatin
keywords: Biomarkers; Grading; Neuroendocrine tumour; Somatostatin; Staging